Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Disc Medicine, Inc. - Common Stock
(NQ:
IRON
)
37.21
-0.74 (-1.95%)
Streaming Delayed Price
Updated: 10:53 AM EDT, Jun 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Disc Medicine, Inc. - Common Stock
< Previous
1
2
Next >
Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 31, 2023
Gainers Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) climbed 49.9% to $4.93 after the company posted a profit for the fourth quarter.
Via
Benzinga
Ensysce Biosciences, AST SpaceMobile, IGM Biosciences And Other Big Stocks Moving Lower On Friday
March 31, 2023
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Why Heron Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
March 24, 2023
Gainers Bird Global, Inc. (NYSE: BRDS) shares rose 58.7% to $0.2250 in pre-market trading after gaining more than 17% on Thursday. Bird announced plans to expand across Greater Toronto area this...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2023
March 23, 2023
Via
Benzinga
Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement
March 18, 2023
Livzon Pharmaceutical Group entered a $127.5 million agreement for China rights to a gastroesophageal reflux disease therapy from Onconic Therapeutics. Meanwhile, Gracell Biotech announced that it had...
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023
February 28, 2023
Via
Benzinga
$2M Bet On PayPal? Check Out These 4 Stocks Insiders Are Buying
February 21, 2023
Although US stocks closed mixed on Friday, there were a few notable insider trades.
Via
Benzinga
Week In Review: Mabwell Out-Licenses Rare Disease Drug For $412.5 Million
January 21, 2023
Mabwell Biosciences out-licensed global rights for a rare disease drug to Disc Medicine of Cambridge, MA in a $412.5 million agreement. Mabwell will receive $10 million upfront, $402.5 million in...
Via
Talk Markets
Stocks Stumbling Out Of 2023's Gate
January 03, 2023
Stocks were unable to fulfill premarket gains, as two familiar foes -- rising rates and high inflation -- dampen investor sentiment to start the new trading year.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023
January 04, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 03, 2023
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.